image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.9553
3.4 %
$ 56.7 M
Market Cap
-0.85
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one LUCD stock under the worst case scenario is HIDDEN Compared to the current market price of 0.955 USD, Lucid Diagnostics Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one LUCD stock under the base case scenario is HIDDEN Compared to the current market price of 0.955 USD, Lucid Diagnostics Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one LUCD stock under the best case scenario is HIDDEN Compared to the current market price of 0.955 USD, Lucid Diagnostics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
2.43 M REVENUE
544.03%
-48.5 M OPERATING INCOME
13.69%
-52.7 M NET INCOME
6.24%
-32.8 M OPERATING CASH FLOW
-10.55%
-221 K INVESTING CASH FLOW
94.62%
29.5 M FINANCING CASH FLOW
1028.30%
1.17 M REVENUE
20.08%
-11.7 M OPERATING INCOME
-4.49%
-12.4 M NET INCOME
-12.41%
-10.2 M OPERATING CASH FLOW
11.38%
-387 M INVESTING CASH FLOW
0.00%
94 K FINANCING CASH FLOW
-99.19%
Balance Sheet Lucid Diagnostics Inc.
image
Current Assets 22.1 M
Cash & Short-Term Investments 18.9 M
Receivables 45 K
Other Current Assets 3.13 M
Non-Current Assets 5.2 M
Long-Term Investments 0
PP&E 2.64 M
Other Non-Current Assets 2.56 M
Current Liabilities 29.4 M
Accounts Payable 1.15 M
Short-Term Debt 15.1 M
Other Current Liabilities 13.2 M
Non-Current Liabilities 199 K
Long-Term Debt 199 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Lucid Diagnostics Inc.
image
Revenue 2.43 M
Cost Of Revenue 8.48 M
Gross Profit -6.05 M
Operating Expenses 42.4 M
Operating Income -48.5 M
Other Expenses 4.18 M
Net Income -52.7 M
RATIOS
-249.18% GROSS MARGIN
-249.18%
-1996.79% OPERATING MARGIN
-1996.79%
-2169.11% NET MARGIN
-2169.11%
2278.93% ROE
2278.93%
-193.13% ROA
-193.13%
-374.55% ROIC
-374.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lucid Diagnostics Inc.
image
Net Income -52.7 M
Depreciation & Amortization 2.5 M
Capital Expenditures -221 K
Stock-Based Compensation 6.82 M
Change in Working Capital 5.68 M
Others 10.5 M
Free Cash Flow -33 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lucid Diagnostics Inc.
image
Wall Street analysts predict an average 1-year price target for LUCD of $2.67 , with forecasts ranging from a low of $2.5 to a high of $3 .
LUCD Lowest Price Target Wall Street Target
2.5 USD 161.70%
LUCD Average Price Target Wall Street Target
2.67 USD 179.14%
LUCD Highest Price Target Wall Street Target
3 USD 214.04%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Lucid Diagnostics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 25, 2023
Sell 286 USD
Lapidus Stanley
Director
- 200
1.43 USD
1 year ago
Sep 26, 2023
Sell 14.7 K USD
Lapidus Stanley
Director
- 10000
1.474 USD
1 year ago
Sep 26, 2023
Sell 14.3 K USD
Lapidus Stanley
Director
- 10000
1.43 USD
1 year ago
Sep 26, 2023
Sell 14.1 K USD
Lapidus Stanley
Director
- 9747
1.45 USD
1 year ago
Sep 20, 2023
Sell 4.94 K USD
Lapidus Stanley
Director
- 3405
1.45 USD
1 year ago
Sep 20, 2023
Sell 593 USD
Lapidus Stanley
Director
- 412
1.44 USD
1 year ago
Sep 21, 2023
Sell 144 USD
Lapidus Stanley
Director
- 100
1.44 USD
1 year ago
Sep 20, 2023
Sell 4.94 K USD
Lapidus Stanley
Director
- 3405
1.45 USD
1 year ago
Sep 20, 2023
Sell 593 USD
Lapidus Stanley
Director
- 412
1.44 USD
1 year ago
Sep 21, 2023
Sell 144 USD
Lapidus Stanley
Director
- 100
1.44 USD
2 years ago
Sep 20, 2022
Sell 29 K USD
Lapidus Stanley
Director
- 17000
1.7067 USD
2 years ago
Sep 20, 2022
Sell 28.7 K USD
Lapidus Stanley
Director
- 16864
1.7 USD
3 years ago
Oct 18, 2021
Bought 8 M USD
PAVmed Inc.
10 percent owner
+ 571428
14 USD
7. News
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW YORK , Jan. 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced it performed a record number of commercial EsoGuard® Esophageal DNA Tests during the fourth quarter of 2024. The preliminary total of 4,042 tests, the highest quarterly test volume in the Company's history, represents a sequential increase of 45 percent from the third quarter 2024 and an annual increase of 84 percent from the fourth quarter of 2023, demonstrating continued growing demand for EsoGuard esophageal precancer testing. prnewswire.com - 2 weeks ago
Lucid Inks New Partnership With VITALExam: Stock to Gain? LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters. zacks.com - 1 month ago
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company now has until June 16, 2025 to meet the requirement. prnewswire.com - 1 month ago
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC (VITALExam), a comprehensive medical care provider for first responders founded by Chief Executive Officer Marci Vitale, DNP, FNP-BC, AGACNP-BC, to enhance access to Lucid's EsoGuard® Esophageal DNA Test for firefighters at risk for esophageal precancer. Lucid and VITALExam launched the partnership with a fully-contracted #CheckYourFoodTube Precancer Testing Event at Tuscaloosa Fire Rescue in Tuscaloosa, AL, as part of Lucid's expanded direct contracting initiative focused on driving near-term EsoGuard revenue. prnewswire.com - 1 month ago
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its CLinical Utility of EsoGuard (CLUE) study has been accepted for publication in the peer-reviewed journal Medicina . This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard® Esophageal DNA Test. prnewswire.com - 1 month ago
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones New convertible debt financing with existing long-term equity shareholders yields ~$18M in net cash proceeds after paying off existing convertible debt NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a convertible debt refinancing transaction that strengthens its balance sheet and extends its cash runway past near-term reimbursement milestones. Lucid issued five-year convertible notes to long-term equity shareholders in an aggregate principal amount of $21.95 million. prnewswire.com - 1 month ago
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a Request for Reconsideration of Local Coverage Determination (LCD) L39256 "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia" to Molecular Diagnostics Program (MolDX), administered by Palmetto GBA, a Medicare Administrative Contractor (MAC) for the Centers for Medicare & Medicaid Services (CMS), to seek coverage for EsoGuard. "This submission is the culmination of many years of persistent hard work by our team and our many clinical research partners, and represents perhaps the most important milestone in Lucid's history," said Lishan Aklog, M.D. prnewswire.com - 2 months ago
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024 at 1:30 p.m. ET. Live and replay webcasts may be accessed on the investor relations section of the Company's website at ir.luciddx.com. prnewswire.com - 2 months ago
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Mark Massaro - BTIG Anthony Vendetti - Maxim Group Mike Matson - Needham Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 2 months ago
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13 th at 8:30 AM EST NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024. Conference Call and Webcast The webcast will take place on Wednesday, November 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. prnewswire.com - 2 months ago
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. prnewswire.com - 2 months ago
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its commercial team has embarked on an expansion of its direct contracting initiative, focusing on programs designed to drive near-term EsoGuard® Esophageal DNA Test revenue, complementing ongoing efforts in traditional reimbursement. These programs include fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets. prnewswire.com - 2 months ago
8. Profile Summary

Lucid Diagnostics Inc. LUCD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 56.7 M
Dividend Yield 0.00%
Description Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Contact One Grand Central Place, New York, NY, 10165 https://www.luciddx.com
IPO Date Oct. 14, 2021
Employees 70
Officers Mr. Shaun M. O'Neill M.B.A. President & Chief Operating Officer Dr. Brian J. deGuzman M.D. Chief Technology & Compliance Officer Mr. Dennis M. McGrath CPA Chief Financial Officer Dr. Sanford D. Markowitz M.D., Ph.D. Co-Founder & Strategic Advisor Dr. Amitabh Chak M.D. Co-Founder & Strategic Advisor Helen Moinova Ph.D. Co-Founder & Strategic Advisor Dr. Lishan Aklog M.D. Chairman & Chief Executive Officer Dr. Joseph Willis M.D. Co-founder & Strategic Advisor Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer Mr. Michael Adam Gordon General Counsel & Secretary